See also:
Profile: Patrick Taylor (Brigham Young University)
  1. Patrick L. Taylor (2010). Overseeing Innovative Therapy Without Mistaking It for Research: A Function-Based Model Based on Old Truths, New Capacities, and Lessons From Stem Cells. Journal of Law, Medicine and Ethics 38 (2):286-302.
    Should innovative therapy occur only within a research paradigm and under institutional review board oversight? The health risks from current human embryonic stem cell clinical applications have raised again a fundamental question addressed first in papers submitted to inform the writing of the Belmont Report. Revisiting the thinking underlying the Belmont Report, together with examining changed circumstances since then, leads to a new model for overseeing innovative therapy based on its unique risks and context, important changes since the Belmont Report, (...)
    Direct download (5 more)  
     
    My bibliography  
     
    Export citation  
  2. Patrick L. Taylor (2009). Scientific Self-Regulation—so Good, How Can It Fail? Science and Engineering Ethics 15 (3):395-406.
    To be a functional alternative to government regulation, self-regulation of science must be credible to both scientists and the public, accountable, ethical, and effective. According to some, serious problems continue in research ethics in the United States despite a rich history of proposed self-regulatory standards and oversight devices. Successful efforts at self-regulation in stem cell research contrast with unsuccessful efforts in research ethics, particularly conflicts of interest. Part of the cause for a lack of success in self-regulation is fragmented, disconnected (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  3. Patrick L. Taylor (2005). The Gap Between Law and Ethics in Human Embryonic Stem Cell Research: Overcoming the Effect of U.S. Federal Policy on Research Advances and Public Benefit. Science and Engineering Ethics 11 (4):589-616.
    Key ethical issues arise in association with the conduct of stem cell research by research institutions in the United States. These ethical issues, summarized in detail, receive no adequate translation into federal laws or regulations, also described in this article. U.S. Federal policy takes a passive approach to these ethical issues, translating them simply into limitations on taxpayer funding, and foregoes scientific and ethical leadership while protecting intellectual property interests through a laissez faire approach to stem cell patents and licenses. (...)
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation